XML 43 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Clinical Trials

The following is a summary of the contractual clinical trials discussed below as of December 31, 2023:

  

Description of

Clinical Trial

  

Type of

Clinical Trial

  

 

Institution

  

Estimated

Start Date

  

Estimated End Date

  

Number of Patients

in Trial

  

Study Objective

  

Clinical Update

  

NCT No.

    

Remaining

Financial

Contractual

Commitment

  
                                         
LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer   Phase 1b   City of Hope and Sarah Cannon   March 2021   March 2026   14 to 36   Determine RP2D   Three patients entered   NCT04560972

$

2,433,000

  
                                         
LB-100 combined with doxorubicin in sarcoma   Phase 1b   GEIS   June 2023   June 2024   9 to 18   Determine MTD and RP2D   One patient entered   NCT05809830    

3,580,000

  
                                         
LB-100 in high grade gliomas   Phase 0 pharmacology study   National Cancer Institute   January 2019   August 2022   7   Determine the penetration of LB-100 into high grade gliomas after IV injection   Closed. No or minimal penetration of LB-100 into high grade gliomas after IV injection   NCT03027388  

(2)
                                         
Doxorubicin with or without LB-100 in sarcoma   Randomized Phase 2   GEIS   July 2024   June 2026   150   Determine efficacy: PFS   Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)   NCT05809830    

(1)
                                         
LB-100 combined with dostarlimab in ovarian clear cell carcinoma   Phase 1b/2   MD Anderson   March 2024   December 2025   21   Determine the survival of patients with ovarian clear cell carcinoma   No patients entered at December 31, 2023   NCT06065462  

(2)
                                         
Total                                   $ 6,013,000  

 

  (1) The financial contractual commitment of the GEIS Randomized Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .
  (2) There is no remaining financial contractual commitment associated with this clinical trial.